Side-by-side peptide comparisons.
Peptide Comparisons
Eloralintide and cagrilintide are both once-weekly amylin analogues in development for obesity. They differ in which receptors they prefer, in who makes them, and in what each has been paired with in trials. Neither is approved.
Peptide Library Editorial · Nov 7, 2026
Read article →
Peptide Comparisons
Eloralintide and retatrutide are both once-weekly investigational injections from Eli Lilly, but they act on different hormone systems. What each one targets, what their trials measured, and why no trial has compared them.
Peptide Library Editorial · Nov 7, 2026
Read article →
Peptide Comparisons
CJC-1295 with DAC binds to albumin and lasts days; the version sold as no DAC (Mod GRF 1-29) lacks that group and is short-acting. Only the DAC form has published human data. What the difference is and what was studied.
Peptide Library Editorial · Nov 7, 2026
Read article →
Peptide Comparisons
Kisspeptin and PT-141 (bremelanotide) both come up in research on sexual desire, but they act on different systems. One is an FDA-approved medicine for one narrow indication; the other has only short academic studies. How they differ.
Peptide Library Editorial · Nov 7, 2026
Read article →Peptide Comparisons
Tesamorelin and CJC-1295 are both GHRH analogues acting on the same pituitary receptor. What separates them is how long they last, which CJC-1295 is meant, and the fact that only one reached approval.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
Semaglutide is an approved GLP-1 receptor agonist; retatrutide is an investigational triple agonist that adds GIP and glucagon. How the mechanisms differ, what each has been tested for, and the head-to-head trial that has not reported yet.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
MT1 and MT2 share a name and a parent hormone, but not a receptor profile or a regulatory history. Melanotan 1 became afamelanotide, an approved implant for a rare light disorder; Melanotan 2 was never approved anywhere.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
Mazdutide and retatrutide both pair GLP-1 with glucagon-receptor agonism; retatrutide adds GIP as a third target. What that difference means, what each trial programme measured, and why no trial has compared them.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
KLOW is GLOW with one extra peptide, KPV. What that fourth component adds, what it does not, why labels and ratios vary between sellers, and the evidence tier of each blend.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
Both raise growth hormone, but through different receptors, and only tesamorelin is an approved medicine. How they work, what the human evidence actually covers, and why a head-to-head answer does not exist.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
AHK-Cu and GHK-Cu are copper tripeptides that differ by a single amino acid. How they bind copper, what each has actually been studied for, and why AHK-Cu's evidence is so much thinner.
Peptide Library Editorial · Sep 26, 2026
Read article →Peptide Comparisons
Adamax is sold as an adamantane-modified version of Semax, the Russian-developed ACTH(4-10) analogue. Semax has a small, mostly Russian-language clinical literature. Adamax has almost none, and even its structure is described inconsistently.
Peptide Library Editorial · Sep 26, 2026
Read article →
Peptide Comparisons
These two are constantly compared, and they are not really alternatives. They act on different receptors to reach the same output, which is why the usual advice is to pair them.
Peptide Library Editorial · Sep 24, 2026
Read article →
Peptide Comparisons
Both prompt the pituitary the same way. One is a full-length analogue that is still an approved medicine; the other is a fragment that was withdrawn from the market.
Peptide Library Editorial · Sep 20, 2026
Read article →
Peptide Comparisons
The headline numbers invite a direct comparison that the evidence does not support. One is approved with head-to-head data; the other is phase 2 with none.
Peptide Library Editorial · Aug 31, 2026
Read article →
Peptide Comparisons
These are sold side by side and are not the same kind of thing. One of them has a documented liver injury signal.
Peptide Library Editorial · Aug 21, 2026
Read article →
Peptide Comparisons
Semax and Selank are constantly discussed together because they share an origin story, not a mechanism. One derives from ACTH, the other from an immune peptide, and the difference shows.
Peptide Library Editorial · Jun 9, 2026
Read article →
Peptide Comparisons
Semaglutide activates one receptor; tirzepatide activates two. In the first head-to-head trial the difference came out to 20.2% versus 13.7% body-weight reduction at 72 weeks. Here is what separates them.
Peptide Library Editorial · Apr 7, 2026
Read article →
Peptide Library